Showing results (61-70 of 134) with videos related to
Sort By:
Pageof 14
Clinical Trials (London, England)|November 29, 2012
Bayesian adaptive design for device surveillanceThomas A Murray, Bradley P Carlin, Theodore C LystigBiometrics|September 29, 1998
Approaches for optimal sequential decision analysis in clinical trialsB P Carlin, J B Kadane, A E GelfandTechnometrics : a Journal of Statistics for the Physical, Chemical, and Engineering Sciences|June 19, 2010
Partitioning degrees of freedom in hierarchical and other richly-parameterized modelsYue Cui, James S Hodges, Xiaoxiao Kong, et al.Statistics in Medicine|May 13, 2005
Does it always help to adjust for misclassification of a binary outcome in logistic regression?Xianqun Luan, Wei Pan, Susan G Gerberich, et al.Clinical Trials (London, England)|October 17, 2017
Multiplicity-adjusted semiparametric benefiting subgroup identification in clinical trialsPatrick M Schnell, Peter Müller, Qi Tang, et al.Statistics in Biopharmaceutical Research|August 23, 2019
Borrowing from Historical Control Data in Cancer Drug Development: A Cautionary Tale and Practical GuidelinesConnor Jo Lewis, Somnath Sarkar, Jiawen Zhu, et al.Statistics in Medicine|May 1, 2015
Incorporation of individual-patient data in network meta-analysis for multiple continuous endpoints, with application to diabetes treatmentHwanhee Hong, Haoda Fu, Karen L Price, et al.Biometrics|March 3, 2011
Multilevel empirical bayes modeling for improved estimation of toxicant formulations to suppress parasitic sea lamprey in the upper great lakesLaura A Hatfield, Steve Gutreuter, Michael A Boogaard, et al.Statistics in Medicine|December 14, 2011
Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trialsLindsay A Renfro, Qian Shi, Daniel J Sargent, et al.Tropical Medicine and Infectious Disease|October 17, 2020
A One Health Approach for Guinea Worm Disease Control: Scope and OpportunitiesMatthew R Boyce, Ellen P Carlin, Jordan Schermerhorn, et al.Pageof 14